Flying Blind: FluMist Gets Green Light Despite Unknown Effectiveness
FluMist hasn’t been available in the US since 2016 when the Advisory Committee on Immunization Practices (ACIP) voted to drop it from the list of recommended vaccines, a decision that was later extended to cover this flu season as well. ACIP’s non-recommendation came after studies conducted by the US Centers for Disease Control and Prevention (CDC) showed that FluMist was not protecting people who received it.
Failing to secure an ACIP recommendation meant that FluMist wouldn’t be fully covered by providers, wouldn’t be stocked as an option by medical professionals and may threaten its overall existence as a viable product for AstraZeneca moving forward. In essence, the FluMist product has been a lost leader for the pharmaceutical company that was now facing a costly loss of approval from the FDA.
During the recent FluMist presentation to the ACIP members, several points were outlined that suggested reasons why another season off the recommended list may still be warranted for AstraZeneca’s product. For instance, a slide titled “Limitations” stated the following bullet points:
- No US VE [vaccine effectiveness] data available for LAIV4 since 2015-2016
- VE [Vaccine effectiveness] for current LAIC4 formulation against H1N1pdm09 unknown
With effectiveness data unknown, Del Bigtree gave public comment minutes before the 14-member ACIP panel voted on whether to recommend the vaccine or cast it off into irrelevance for a third season in a row. Bigtree stated:
“Removing FluMist was a big story in this country. And unlike other choices you make, the public was very aware it was taken away. So when you put it back, the media is going to be very interested in why. And when you have to discuss why, as the CDC, your response looks very flimsy to me that well, they changed the H1N1 and even though there’s no proof of its effectiveness, we’re gonna go ahead and recommend it.”
After the vote to recommend FluMist, the ACIP members appeared to do an about-face and actively engage in discussion on how to massage the messaging around their new LAIV4 recommendation. Their motivations appeared to be the future avoidance of public backlash and bad press in the event of an H1N1 flop at the hands of their newly approved flu solution with unknown effectiveness.
Talk was had by ACIP members on how to keep their official recommendation without actually using the words “recommendation” so providers can stock the FluMist product, insures can charge for it and AstraZeneca can reestablish market presence while not lose their FDA approval. Above all, ACIP can say they never officially attached the words recommendation upon the vaccine’s status. The mainstream reporting from Time, Statnews.com and NBC News ran with ACIP’s doublespeak recommendation messaging:
“It’s better than nothing” Dr. Grace Lee ACIP member and Professor of pediatrics at Stanford University School of Medicine stated.
During the current flu season, one which has been billed the worst in over a decade, it appears both confusing and irresponsible to green-light an old, previously questionable vaccine [LAVI4] with current unknown effectiveness. With ACIP’s vote, the message sent to the public looking for science-based disease control and prevention solutions to future flu-like illnesses appears to be that an unknown hope is better than nothing.